Biogen offloads nearly $600M in Cambridge real estate — making room for a Broad Institute expansion
The fallout of the Covid-19 pandemic is still playing out more than two and a half years after it began, and the newest effects impacting the biopharma industry fall directly on real estate.
Real estate developer BXP said Wednesday that it acquired a building in Cambridge, MA from Biogen for $592 million. The building, located at 125 Broadway in Cambridge, MA, is in Cambridge’s biotech hub in Kendall Square, home to other companies such as Thermo Fisher Scientific and Moderna.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.